BAYRY - Orion wins EU approval for darolutamide for additional indication in prostate cancer

The European Commission has granted marketing authorization in the European Union (EU) for Orion's ( OTCPK:ORINY ) darolutamide, an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).

The EU approval is based on the positive results from the Phase III ARASENS trial, which demonstrated that darolutamide plus ADT in combination with docetaxel significantly reduced the risk of death by 32.5% compared to ADT with docetaxel, in patients with mHSPC.

Additionally, the darolutamide combination showed consistent benefits across clinically relevant secondary endpoints, with the overall incidence of treatment-emergent adverse events being similar between treatment arms.

Darolutamide is developed jointly by Orion and Bayer ( OTCPK:BAYRY ).

For further details see: